Neuroprotective Properties of Dimethyl Fumarate Measured by Optical Coherence Tomography in Non-inflammatory Animal Models
Open Access
- 13 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11
Abstract
While great advances have been made in the immunomodulatory treatment of multiple sclerosis (MS), there is still an unmet need for drugs with neuroprotective potential. Dimethyl fumarate (DMF) has been suggested to exert both immunomodulatory and neuroprotective effects in MS. To investigate if DMF has neuroprotective effects independent of immunomodulation we evaluated its effects in the non-inflammatory animal models of light-induced photoreceptor loss and optic nerve crush. This might also reveal applications for DMF besides MS, such as age related macular degeneration. Retinal neurodegeneration was longitudinally assessed by in vivo retinal imaging using optical coherence tomography (OCT), and glutathione (GSH) measurements as well as histological investigations were performed to clarify the mode of action. For light-induced photoreceptor loss, one eye of C57BL/6J mice was irradiated with a LED cold light lamp while for optic nerve crush the optic nerve was clamped behind the eye bulb. The other eye served as control. GSH was measured in the optic nerve, choroid and retina and immunohistological staining of retinal microglia (Iba1) was performed. Mice were treated with 15 or 30 mg DMF/kg bodyweight or vehicle. While no protective effects were observed in optic nerve crush, in the light-induced retinal degeneration model DMF treatment significantly reduced retinal degeneration. In these mice, GSH levels in the retina and surrounding choroid were increased and histological investigations revealed less microglial activation in the outer retinal layers, suggesting both antioxidant and anti-inflammatory effects.Keywords
Funding Information
- Biogen
This publication has 35 references indexed in Scilit:
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisNew England Journal of Medicine, 2012
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- Effects of dimethyl fumarate on neuroprotection and immunomodulationJournal of Neuroinflammation, 2012
- Longitudinal In Vivo Imaging of Retinal Ganglion Cells and Retinal Thickness Changes Following Optic Nerve Injury in MicePLOS ONE, 2012
- Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 PathwayThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Optic Nerve Crush Mice Followed Longitudinally with Spectral Domain Optical Coherence TomographyInvestigative Ophthalmology & Visual Science, 2011
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- In Vivo Quantitative Evaluation of the Rat Retinal Nerve Fiber Layer with Optical Coherence TomographyInvestigative Ophthalmology & Visual Science, 2009
- Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritisJournal of Neurology, 2007
- Oral fumaric acid esters for the treatment of active multiple sclerosis: an open‐label, baseline‐controlled pilot studyEuropean Journal of Neurology, 2006